Lab-on-a-chip and Microarrays (Biochip) Market, By Type (Lab-on-a-chip and Microarray), By Product (Instruments, Reagents and Consumables, and Software and Services), By Application (Clinical Diagnostics, Drug Discovery, Genomics and Proteomics, and Other Application), By End User (Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostics Centers, and Academic and Research Institutes), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)-

Published In : Mar 2023

Code : CMI515

Pages :151

Formats :

Excel and PDF

Industry : Medical Devices

Regional Analysis

Global Lab-on-a-chip and Microarrays (Biochip) Market: Regional Insights

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa

Based on geography, the global lab-on-a-chip and microarrays (biochip) market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the increasing incidence of chronic diseases, increasing application of proteomics and genomics, and robust healthcare infrastructure in the region. For instance, according to the US Centers for Disease Control and Prevention (CDC), chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. Such a high number of people living with chronic disease in the U.S. has increased the use of proteomics and genomics, contributing to the growth of the market in the region.

Europe and Asia Pacific are also expected to witness robust growth in the global lab-on-a-chip and microarrays (biochip) market due to the rise in burden of chronic diseases, increasing demand for point-of-care (POC) testing, increasing application of proteomics and genomics in cancer research, and increasing adoption of personalized medicines in these regions. For instance, according to the cancer report by Indian Council of Medical Research (ICMR), India’s cancer cases could increase by 12% in the next five years (2020-25), with over 1.5 million people expected to suffer from non-communicable disease by 2025, up from 1.39 million in 2020.